These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34446858)

  • 21. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
    Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
    EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 23. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A; Ookura M; Zokumasu K; Ueda T
    Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
    Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
    Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
    Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.
    Leung AY; Man CH; Kwong YL
    Leukemia; 2013 Feb; 27(2):260-8. PubMed ID: 22797419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
    Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
    Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
    Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
    PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
    Weisberg E; Ray A; Nelson E; Adamia S; Barrett R; Sattler M; Zhang C; Daley JF; Frank D; Fox E; Griffin JD
    PLoS One; 2011; 6(9):e25351. PubMed ID: 21980431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
    Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
    Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
    Yang X; Sexauer A; Levis M
    Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
    Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
    Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.